Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;43(4):679-687.
doi: 10.1097/IAE.0000000000003698.

UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION

Mohamed Kamel Soliman  1   2 , Javier Zarranz-Ventura  3 , Usha Chakravarthy  4 , Martin McKibbin  5 , Christopher Brand  6 , Geeta Menon  7 , Helena Cilliers  8 , Salim Natha  9 , Adam Ross  10 , Mahmoud Sarhan  11 , Aires Lobo  12 , Victor Chong  13 , Sajjad Mahmood  14 , Niaz Islam  15 , Toks Akerele  16 , Ahmed Shakarchi  17 , Ahmed Sallam  17   18 ; United Kingdom Ozurdex in Retinal Vein Occlusion Electronic Medical Records (UK Ozurdex RVO EMR) Users Group
Affiliations

UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION

Mohamed Kamel Soliman et al. Retina. .

Abstract

Purpose: To study the treatment patterns, visual outcomes and safety profile of intravitreal dexamethasone implant (IDI) used for the treatment of macular edema secondary to retinal vein occlusion.

Methods: Up to 2 years of routinely collected anonymized data within electronic medical record systems were remotely extracted from 16 centers. The outcome measures include visual outcome, number of injections, and safety measures, including the rate of intraocular pressure (IOP) rise, frequency of IOP-lowering medication usage, and cataract surgery rates.

Results: The study included 688 eyes (44.4%) with central retinal vein occlusion and 862 eyes (55.6%) with branch retinal vein occlusion; 1,250 eyes (80.6%) were treatment naive and 28% (275/989) had high IOP or were on IOP-lowering medications before IDI use. It was found that 31% (476) of eyes received two injections, and 11.7% (182) and 3.7% (58) of eyes received three and four injections, respectively. The mean baseline Snellen visual acuity improved from 20/125 to 20/40 after the first injection. The probability of cataract surgery was 15% at 24 months. The proportion of eyes with ≥10 mmHg change from baseline was higher in phakic (14.2%) compared with pseudophakic eyes (5.4%, P = 0.004). Three eyes required IOP filtering surgery (0.2%).

Conclusion: The visual results of IDI in eyes with macular edema secondary to retinal vein occlusion in the real world are comparable to those of clinical trial setting. Increased IOP in eyes with preexisting ocular hypertension or glaucoma can be controlled with additional medical treatment. Intraocular pressure rise with IDI may be more frequent in phakic than in pseudophakic eyes.

PubMed Disclaimer

References

    1. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1146.e3.
    1. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Ophthalmology 2011;118:2453–2460.
    1. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. 2011. Retrieved 12/27/2020, 2020, from https://www.nice.org.uk/guidance/ta229 .
    1. Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (ozurdex): the safodex study. Incidence and risk factors of ocular hypertension. Retina 2017;37:1352–1359.
    1. Pommier S, Meyer F, Guigou S, et al. Long-term real-life efficacy and safety of repeated Ozurdex ® injections and factors associated with macular edema resolution after retinal vein occlusion: the REMIDO 2 study. Ophthalmologica 2016;236:186–192.